Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2014 1
2015 5
2016 6
2017 2
2018 2
2019 1
2020 3
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year

Citations

3 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
Kim RG, Loomba R, Prokop LJ, Singh S. Kim RG, et al. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039. Epub 2017 May 4. Clin Gastroenterol Hepatol. 2017. PMID: 28479502 Free PMC article. Review.
RESULTS: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. ...In patients with CLD without cirrhosis, statin use was associated with a nonsignificant (58% lower) risk of development
RESULTS: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. ...In patien
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Fujiwara N, et al. J Hepatol. 2018 Mar;68(3):526-549. doi: 10.1016/j.jhep.2017.09.016. Epub 2017 Oct 6. J Hepatol. 2018. PMID: 28989095 Free PMC article. Review.
Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). ...Thus, early detection and prevention of HCC development is, in principle, t
Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk
Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Yang YH, et al. J Hepatol. 2015 Nov;63(5):1111-7. doi: 10.1016/j.jhep.2015.07.006. Epub 2015 Jul 18. J Hepatol. 2015. PMID: 26196278
Previous studies have indicated that statins can prevent the progression of hepatic fibrosis in patients with hepatitis C virus (HCV) infection and advanced hepatic fibrosis, however data is lacking on patients who ha …
Previous studies have indicated that statins can prevent the progression of hepatic fibrosis in patients with hepati
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.
Simon TG, Butt AA. Simon TG, et al. World J Gastroenterol. 2015 Jul 21;21(27):8293-303. doi: 10.3748/wjg.v21.i27.8293. World J Gastroenterol. 2015. PMID: 26217081 Free PMC article. Review.
The hepatitis C virus (HCV) is one of the most common causes of chronic liver disease and the leading indication for liver transplantation worldwide. ...HMG CoA Reductase inhibitors, or statins, have been shown to pla …
The hepatitis C virus (HCV) is one of the most common causes of chronic liver disease and the leading indication …
Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection.
Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Lee TY, et al. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2784-2792.e7. doi: 10.1016/j.cgh.2020.04.036. Epub 2020 Apr 28. Clin Gastroenterol Hepatol. 2020. PMID: 32360983
BACKGROUND & AIMS: Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for its effects on risk of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). ...Cumulative incidence o …
BACKGROUND & AIMS: Aspirin therapy has been associated with reduced risk of colon cancer, but there is only limited evidence for …
Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.
Lavu S, Therneau TM, Harmsen WS, Mara KC, Wongjarupong N, Hassan M, Ali HA, Antwi S, Giama NH, Miyabe K, Roberts LR. Lavu S, et al. Hepatology. 2020 Oct;72(4):1298-1309. doi: 10.1002/hep.31146. Epub 2020 Oct 9. Hepatology. 2020. PMID: 32119126 Free PMC article.
Hepatitis C virus infection (OR, 15.84; 95% confidence interval [CI], 4.06-61.87; P < 0.001) was the most significant risk factor for pCCA followed by inflammatory bowel disease and cirrhosis, whereas other liver disease, includ
Hepatitis C virus infection (OR, 15.84; 95% confidence interval [CI], 4.06-61.87; P < 0.001) was the most sig
A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.
Tapper EB, Parikh ND, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. Tapper EB, et al. Hepatology. 2018 Oct;68(4):1498-1507. doi: 10.1002/hep.29628. Epub 2018 May 14. Hepatology. 2018. PMID: 29091289 Free article.
Accordingly, we aimed to develop a tool to risk-stratify patients for HE development. We studied a population-based cohort of all patients with cirrhosis without baseline HE (n = 1,979) from the Veterans Administration from Michigan, Indi …
Accordingly, we aimed to develop a tool to risk-stratify patients for HE development. We studied a population-ba …
Amiodarone and risk of liver cirrhosis: a nationwide, population-based study.
Huang CH, Lai YY, Kuo YJ, Yang SC, Chang YJ, Chang KK, Chen WK. Huang CH, et al. Ther Clin Risk Manag. 2019 Jan 10;15:103-112. doi: 10.2147/TCRM.S174868. eCollection 2019. Ther Clin Risk Manag. 2019. PMID: 30666120 Free PMC article.
Patients with hepatitis B virus and hepatitis C virus infections are at a high risk for developing liver cirrhosis. However, the relationship between this treatment and risk of liver cirrhosis
Patients with hepatitis B virus and hepatitis C virus infections are at a high risk for
23 results